HCW Biologics is a clinical-stage biopharmaceutical company in Miramar, Florida developing fusion immunotherapeutics for diseases driven by chronic, low-grade inflammation, or inflammaging. Its TOBI (Tissue factOr-Based fusIon) discovery platform is used to build multi-functional fusion proteins that combine several immune-modulating activities in a single molecule. Lead candidate HCW9218 is a bifunctional immunotherapeutic that neutralizes TGF-beta while stimulating immune cells, in Phase 1b/2 study in pancreatic cancer; HCW9302 is an IL-2 fusion protein complex in a Phase 1 trial for alopecia areata. The company was founded in 2018 by Hing C. Wong and is publicly traded on Nasdaq under the ticker HCWB.